Lv1
10 积分 2021-10-17 加入
Microcatheter-Assisted Trabeculotomy Combined With Deep Sclerectomy and Trabeculectomy in Young to Middle-Aged Adults With Advanced Primary Open-Angle Glaucoma: 1-Year Result
1年前
已完结
Pan-cancer analysis reveals potential of FAM110A as a prognostic and immunological biomarker in human cancer
1年前
已完结
VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma
1年前
已完结
Pan-cancer analysis reveals potential of FAM110A as a prognostic and immunological biomarker in human cancer
1年前
已完结
560P Neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced cervical cancer (NACI): A prospective, single-arm, phase II trial
1年前
已关闭
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
1年前
已完结
Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
1年前
已完结
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
1年前
已完结
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
1年前
已完结
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)
1年前
已完结
皖公网安备34019202002308
